GFS Advisors LLC Takes $12.84 Million Position in Pfizer Inc. (NYSE:PFE)

GFS Advisors LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 484,009 shares of the biopharmaceutical company’s stock, valued at approximately $12,841,000. Pfizer makes up 2.0% of GFS Advisors LLC’s investment portfolio, making the stock its 16th largest position.

A number of other large investors also recently bought and sold shares of the business. Quarry LP bought a new position in Pfizer in the 2nd quarter worth about $31,000. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Pfizer by 60.3% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 583,600 shares of the biopharmaceutical company’s stock worth $16,329,000 after purchasing an additional 219,600 shares in the last quarter. Central Pacific Bank Trust Division grew its stake in Pfizer by 71.8% in the third quarter. Central Pacific Bank Trust Division now owns 9,286 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 3,880 shares in the last quarter. Czech National Bank raised its position in Pfizer by 6.9% during the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after purchasing an additional 74,737 shares in the last quarter. Finally, Canandaigua National Bank & Trust Co. lifted its holdings in shares of Pfizer by 23.6% in the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 235,277 shares of the biopharmaceutical company’s stock worth $6,809,000 after buying an additional 44,957 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim lowered their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 1.5 %

Pfizer stock opened at $26.51 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $150.20 billion, a PE ratio of 35.82, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock has a 50-day moving average of $26.25 and a two-hundred day moving average of $27.89. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same period last year, the firm posted ($0.17) EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.